GENFIT S A/ADR (NASDAQ:GNFT) had its price objective decreased by HC Wainwright to $72.00 in a report issued on Monday, The Fly reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s target price indicates a potential upside of 182.69% from the stock’s previous close.

Separately, Barclays initiated coverage on GENFIT S A/ADR in a research report on Monday. They set an “overweight” rating and a $55.00 target price for the company.

Shares of GENFIT S A/ADR stock opened at $25.47 on Monday. GENFIT S A/ADR has a 1 year low of $20.81 and a 1 year high of $26.08.


Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology. The company's lead products include Elafibranor, which is in pivotal Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as in Phase 2 study in patients with primary biliary cholangitis; and Nitazoxanide that is in Phase 2 proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis.

Further Reading: Call Option Volume

The Fly

Receive News & Ratings for GENFIT S A/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENFIT S A/ADR and related companies with's FREE daily email newsletter.